Alvotech Resolves Global Patent Disputes for Eylea® 2mg Biosimilar, Gains Worldwide Manufacturing Rights

Settlement with Regeneron and Bayer removes patent barriers, enabling Alvotech to supply its aflibercept biosimilar globally pending regulatory approvals.

Valye News Insights

Alvotech finalized a licensing and settlement agreement with Regeneron and Bayer resolving all remaining patent disputes worldwide for its Eylea® 2mg (aflibercept) biosimilar. This consolidates Alvotech’s ability to manufacture and supply the biosimilar across key markets, including the European Economic Area, United Kingdom, Japan, and the United States pending regulatory approval.

From a Valye AI perspective, this settlement removes a major legal risk, unlocking Alvotech’s global commercialization strategy. However, regulatory approvals and successful market launches remain critical for revenue realization.

Potential scenarios include smooth U.S. regulatory approval by late 2026 enabling timely market entry, or delays and market access challenges limiting near-term impact despite the settlement. Competitive dynamics or new legal challenges could also emerge.

Key signals to monitor include regulatory progress, sales volumes post-launch, partnership execution, and patent landscape stability to assess ongoing commercial risks and opportunities. The materiality gate is whether this shows up in orders, margins, or guidance.

Key numbers

• Q4 2026 — U.S. license entry date pending regulatory approval
• 40 mg/mL — concentration of aflibercept biosimilar
• January 29, 2026 — date of settlement announcement

What changed

• Settlement agreement with Regeneron and Bayer resolves all remaining patent disputes worldwide
• Global manufacturing and supply rights obtained for aflibercept biosimilar
• Cleared markets extended to European Economic Area, United Kingdom, Japan, and pending U.S. entry

Bottom line: The patent settlement enables Alvotech’s global commercialization of its aflibercept biosimilar, but material upside depends on regulatory approvals and successful launches in key markets.

Key points

• Alvotech’s biosimilar to Eylea® 2mg holds marketing approval in the European Economic Area, United Kingdom, and Japan.
• The settlement complements a prior U.S. licensing arrangement with a Q4 2026 entry date conditional on regulatory clearance.
• Resolving patent disputes globally minimizes legal impediments to commercial production and supply.
• The agreement allows collaboration with global commercial partners without patent constraints.
• Regulatory approval remains critical for the U.S. market launch.
• The biosimilar concentration is 40 mg/mL aflibercept solution, matching the reference product.

Commercial and regulatory context

• The biosimilar targets Eylea®, an anti-VEGF treatment for retinal diseases.
• Patent settlements are crucial to avoid costly litigation and market entry delays.
• U.S. entry timing in Q4 2026 aligns with patent expiry and pending regulatory clearance.
• Approval in Europe, Japan, and the U.K. positions Alvotech for incremental revenue.
• Partnerships are essential to leverage manufacturing and distribution globally.

Risks / what to watch

• U.S. regulatory approval is pending and necessary for Q4 2026 market entry.
• Delays in manufacturing scale-up or supply chain could impact availability.
• Emerging biosimilars or patent law changes could alter the competitive landscape.
• Market uptake depends on pricing, reimbursement, and physician adoption.
• Unforeseen legal challenges could arise despite the settlement.
• Execution risks exist in securing and managing global commercial partnerships.

News Context

• Alvotech reached a global licensing and settlement agreement with Regeneron and Bayer for its Eylea® 2mg biosimilar.
• The agreement resolves all remaining worldwide patent disputes related to the aflibercept biosimilar.
• The product holds marketing approvals in the European Economic Area, United Kingdom, and Japan.
• A prior agreement secured a U.S. license entry date of Q4 2026, contingent on regulatory approval.
• Alvotech now has global rights to manufacture and supply the biosimilar to commercial partners worldwide.
• The biosimilar is formulated as aflibercept 40 mg/mL solution.
• The announcement was made on January 29, 2026.

Sources

• Press release

This article is general in nature and often relies heavily on company press releases and other third-party public sources, which may be promotional, incomplete, or occasionally inaccurate. It also incorporates AI-generated analysis, assumptions, scenarios, and broader public background context to help place the news in a wider industry narrative. As a result, it may contain errors or omissions. Always verify important details using primary sources (company filings, official releases, and direct statements). This is not financial advice and is not a recommendation to buy or sell any security.

Disclaimer: Research-only. Not investment advice.